Corxel Pharmaceuticals closed a $287 million Series D1 round to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The company cited positive Phase II weight‑loss results (≈9.7% at 16 weeks) and plans Phase III programs in China and the U.S. The financing drew participation from crossover and healthcare investors including RTW, RA Capital and HBM Healthcare. Separately, the UK Medicines and Healthcare products Regulatory Agency (MHRA) reported seizing nearly 20 million doses of illegally traded medicines in 2025, including GLP‑1 drugs. The enforcement action underscores growing regulatory focus on unregulated supply chains for high‑demand cardiometabolic and weight‑loss medications, creating commercial and compliance risks for manufacturers and distributors.